SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.
Breezula (cb-03-01) and kx-826 are discussed as hair loss treatments. Kx-826 is available on Kintor's website, while Breezula is available on the grey market.
Breezula (clascoterone) is expected to be available by late 2026, showing good long-term results with minimal side effects. KX-826 (pyrilutamide) acts faster but is still in earlier development stages.
SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.
SCUBE3 is a promising new molecule that can restart hair growth by reawakening dormant hair follicles. Users express skepticism about its availability timeline, with some hoping for release by 2026.
Hair loss treatments discussed include promising Pyr available online and Verteporfin dosing after FUE for follicle regeneration, but no updates on SCUBE3.
Breezula is being sold at Anagen Inc and Universal Labs, and users are discussing their experiences and results with it. There is also interest in the formulation process and inquiries about PP405.
The conversation is about a potential new hair loss treatment called Breezula CB-03-01. Users are discussing updates on its development and sharing personal experiences with making or using it.
KX-826/pyrilutamide is undergoing an additional one-year safety and efficacy trial in China after a six-month study. Some participants speculate on the reasons for the extended trial and discuss the potential of other treatments.
Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.
The conversation discusses the effectiveness of commercial Low-Level Laser Therapy (LLLT) devices for hair growth, suggesting they are underpowered compared to the ideal energy output shown in medical research. A user plans to build a custom helmet that meets the required specifications for effective treatment.
A breakthrough in hair follicle cultivation using induced pluripotent stem cells (iPSCs) has been achieved, producing large hair follicles suitable for transplantation. Clinical trials for this hair multiplication technology are planned in partnership with Yinguan Biotechnology.
Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.
Spraying pyrilutamide on the crown area shows noticeable improvement compared to using a dropper. Applying directly to the vertex is challenging without wasting the product.
SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.
Comparing two upcoming topical hair loss treatments, Fluridil and Breezula, to determine which is most effective for treating hair loss, taking into consideration factors such as price, side effects, potential for hair growth, convenience of application, smell, greasiness, and styling after use.
Hair loss discussion includes LLLT treatments and a satirical condition called PLLLTS, causing patients to resemble lighthouses and attract moths. Some users express concern about others taking the satire seriously.
The conversation is about comparing the effectiveness of fluridil and clascoterone in preventing hair loss and inquiring about their use as standalone treatments. There is a question about the concentration of the fluridil brand for efficacy.
PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.
The conversation is about finding an affordable and effective low level laser therapy device for hair loss, with a preference for a cap but open to a comb.
Breezula is a potential hair loss treatment, but recent updates suggest it may not be as promising as initially thought. Some users express skepticism about its effectiveness based on past results.
User seeks participants for Verteporfin group buy. Verteporfin, FDA approved, may regenerate hair follicles and sweat glands through heavy microneedling.
Breezula shows promising hair growth results, with up to 539% increase in hair count compared to placebo, and regulatory submissions are planned in the US and EU. Users are cautiously optimistic, noting the potential for Breezula to replace finasteride by targeting DHT without systemic effects.
A user shared their positive experience with the Omnilux Red Light mask for skin and potential hair benefits, while also using Minoxidil, Dutasteride, and RU58841. They recommend the mask for those interested in skincare and red light therapy, despite being unsure of its effectiveness for hair growth.
A user is comparing Capillus Ultra and Capillus ONE for hair loss treatment, questioning if the number of diodes matters. Another user suggests the OMG helmet as the only worthwhile option.